Abstract

Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1

Author(s): Allen Loyd V Jr

Issue: Mar/Apr 2017 - Volume 21, Number 2

Page(s): 127-130

Download in electronic PDF format for $75
  • Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1 Page 1
  • Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1 Page 2
  • Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1 Page 3
  • Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1 Page 4

Abstract

Three-dimensional printing quickly became a standard tool in the automotive, aerospace, and consumer goods industries and, recently, has begun gaining traction in pharmaceutical manufacturing. 3D printing has steadily grown, introducing a new element into dosage form development, and has received a boost with U.S. Food and Drug Administration (FDA) approval of the 3D-printed orodispersible tablet, Spritam (levetiracetam). This part 1 of a 3-part article introduces 3D printing and its application to pharmacy.

Related Keywords

  • 3D printing
  • pharmaceutical manufacturing
  • dosage form development
  • U.S. Food and Drug Administration
  • FDA
  • orodispersible tablet
  • levetiracetam
  • complex dosage forms
  • personalization
  • on-demand compounding
  • delayed release
  • transdermal administration
  • long-acting implants
  • modified release
  • multiple release
  • combination drug products
  • customized dosage forms
  • decentralization
  • decentralized manufacturing
  • additive manufacturing
  • stereolithography file format
  • .stl
  • rapid disintegration
  • low-stability drugs

Related Categories

  • LEGAL
  • TECHNOLOGY
  • DOSAGE FORMS/DRUG CARRIERS

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2017
Pg. 127-130
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 1
Author(s): Allen Loyd V Jr
May/Jun 2017
Pg. 215-220
Basics of Compounding: 3D Printing--Pharmacy Applications, Part 2
Author(s): Allen Loyd V Jr
Sep/Oct 2017
Pg. 388-392
Basics of Compounding: 3D Printing--Pharmacy Applications: Geometric Shape Effects on 3D Printing
Author(s): Allen Loyd V Jr
Jul/Aug 2017
Pg. 293-298
Basics of Compounding: 3D Printing: Pharmacy Applications, Part 3: Compounding, Formulation Considerations, and the Future
Author(s): Allen Loyd V Jr
Nov/Dec 2022
Pg. 516-521
Formulation Development of Modafinil Sprinkle Dosage Form: Study on the Effect of Food on Dosage
Author(s): Kumaravelrajan Rajagopal, Karthik B, Venkatasan Suba
Jul/Aug 2016
Pg. 351
View Sample
Discrepancies in the Law and the U.S. Food and Drug Administration Pharmacy Compounding Compliance Policy Guidelines
Author(s): Allen Loyd V Jr
Mar/Apr 2017
Pg. 95-102
U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies
Author(s): Yoch Doug
Jan/Feb 2017
Pg. 47-56
Basics of Sterile Compounding: Biopharmaceutics of Injectable Dosage Forms
Author(s): Akers Michael J
Sep/Oct 2017
Pg. 356
PreScription: 2017 Pharmacy Compounding Issues: The U.S. Food and Drug Administration, Harzardous Drugs, and Wasted Drugs
Author(s): Allen Loyd V Jr
Mar/Apr 2022
Pg. 163-174
Molding as Innovative Technology for Personalized Tablet Production
Author(s): Mady Omar Y, Al-Shoubki Adam A, Hagag Youssef, Ibrahim Bakry, Donia Ahmed A
Nov/Dec 2023
Pg. 474-481
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients
Author(s): Allen Loyd V Jr
Jul/Aug 2015
Pg. 303-305
U.S. Food and Drug Administration Proposed Guidance Document: Compounding Animal Drugs from Bulk Substances
Author(s): Miller David G
Nov/Dec 2015
Pg. 487-488
U.S. Food and Drug Administration "Evaluation Criteria" for Difficult to Compound Drugs
Author(s): Allen Loyd V Jr
Jan/Feb 2019
Pg. 32-33
U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line
Author(s): Snow Stephen T, Stannard Robert W, Bellis Jennifer, Moss Carrie A
Jul/Aug 2020
Pg. 296-297
Finally: A Final U.S. Food and Drug Administration Memorandum of Understanding, but It's Flawed
Author(s): Brunner Scott
May/Jun 2014
Pg. 208
The U.S. Food and Drug Administration Responds to the International Academy of Compounding Pharmacists' Outsourcing Letter
Author(s): Miller David G
Mar/Apr 2014
Pg. 101-111
Pharmaceutical Compounding or Pharmaceutical Manufacturing? A Regulatory Perspective
Author(s): Timko Robert J, Crooker Philip EM
Nov/Dec 2014
Pg. 479-484
Basics of Compounding: Unique and Special Characteristics of Sterile Dosage Forms
Author(s): Akers Michael J
Sep/Oct 2015
Pg. 389-390
Nominations of Difficult to Compound Drugs to the U.S. Food and Drug Administration--Pharmacy Compounding Advisory Committee: Part 1
Author(s): Allen Loyd V Jr
Jul/Aug 2013
Pg. 312-322
Basics of Compounding: Foam Dosage Forms
Author(s): Allen Loyd V Jr